Investor bets are shifting between the two biotech firms, Moderna and Exelixis, Inc.
1 report, 1 independent
Updated Sep 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Investor bets are shifting between the two biotech firms, Moderna and Exelixis, Inc.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Moderna
American biotechnology company
Related events
- Moderna, Pfizer, and Merck are part of a healthcare rotation story, with Moderna outperforming Pfizer in current stock gains.
- Moderna and Iovance Biotherapeutics, alongside Dell, SanDisk, and MaxLinear, were noted among top stock gainers.
- Moderna and Merck reported a landmark result from their melanoma study, while SanDisk and Dell were discussed in stock market analysis.
- Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.
- Moderna's stock gains are being driven by FDA approval and the broader growth of AI businesses, as a Nasdaq constituent.